文献速递外周动脉疾病

他汀类药物对因慢性肢体威胁性缺血接受外周血管内介入治疗患者生存及保肢的影响

Impact of Statins on Survival and Limb Salvage in Patients Undergoing Peripheral Endovascular Intervention for Chronic Limb-Threatening Ischemia.
PubMed 文献 · Ann Vasc Surg · 2022-12-09

基于美国血管质量倡议数据库2010-2016年因慢性肢体威胁性缺血行外周血管内介入的8402例患者,比较全程使用他汀与未使用他汀者的结局。他汀使用与3年总生存改善独立相关(匹配后HR 0.50,95%CI 0.27-0.92),但3年保肢和无截肢生存无显著差异;在肾衰竭亚组中他汀与保肢改善相关。作者认为除非不耐受,所有患者均应考虑他汀,并需进一步研究高危亚组。

要点

  • 全程他汀使用与慢性肢体威胁性缺血介入后3年总生存改善独立相关。
  • 总体人群3年保肢和无截肢生存在他汀组与未使用组间无显著差异。

核心结论

  • 他汀使用与因慢性肢体威胁性缺血行外周血管内介入患者的总生存改善独立相关,除非不耐受否则应考虑用于所有患者。
  • 他汀使用与终末期肾病患者保肢改善相关,该领域需进一步研究,尤其是他汀对高危慢性肢体威胁性缺血亚组的影响。

研究设计与样本

  • 查询美国国家血管质量倡议数据库2010-2016年因慢性肢体威胁性缺血行指数外周血管内介入的患者,随访至2020年。
  • 共纳入8402例患者的9089次指数介入,按他汀使用分为全程他汀组(6591例患者、7149次介入)和未使用他汀组(1811例患者、1940次介入)。
  • 构建倾向性评分匹配模型,采用卡方检验、Kaplan-Meier生存分析和Cox回归分析比较组间差异。

主要发现

  • 平均年龄69±12岁,58%为男性。
  • 3年总生存:全程他汀组92.9%±0.9 vs 未使用他汀组91.1%±2.2(P=0.003),HR 0.66(95%CI 0.44-0.99,P=0.047);倾向性评分匹配后全程他汀组95.1%±0.2% vs 未使用他汀组90.8%±0.3%(P=0.02),HR 0.50(95%CI 0.27-0.92,P=0.025)。
  • 匹配前3年保肢:全程他汀组83.7%±0.8 vs 未使用他汀组84.0%±1.7(P=0.89),HR 1.09(95%CI 0.88-1.35,P=0.44);匹配前3年无截肢生存:全程他汀组77.2%±1.1% vs 未使用他汀组76.1%±2.5%(P=0.17),HR 0.97(95%CI 0.79-1.18,P=0.74)。
  • 倾向性评分匹配后3年无截肢生存:全程他汀组80.2%±2.8% vs 未使用他汀组74.7%±3.9%(P=0.53),HR 0.92(95%CI 0.72-1.19,P=0.54);匹配后3年保肢:全程他汀组85.3%±1.9% vs 未使用他汀组83.5%±2.6%(P=0.51),HR 1.08(95%CI 0.83-1.4,P=0.57)。

临床怎么用

  • 作者认为,因慢性肢体威胁性缺血行外周血管内介入的患者除非不耐受,均应考虑他汀治疗。
  • 作者建议在高危慢性肢体威胁性缺血亚组(如终末期肾病)中进一步研究他汀治疗的影响。

局限性

  • 原文结论指出该领域需进一步研究,尤其是他汀治疗对高危慢性肢体威胁性缺血亚组的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Statin therapy is recommended in all patients with peripheral arterial disease (PAD). Its impact on reduction in mortality has been well-documented, yet effect on limb-specific outcomes has been less conclusive. Differences among PAD subgroups or variability of statin use may contribute to the inconsistent findings. We evaluated statin use in patients who underwent peripheral endovascular intervention (PVI) for chronic limb-threatening ischemia (CLTI) and its impact on overall survival (OS), amputation-free survival (AFS) and limb salvage (LS). METHODS: The national Vascular Quality Initiative was queried for the index PVI for CLTI during the period 2010-2016; follow-up (FU) through 2020. Demographics, comorbidities, operative details, and FU status were recorded. Patients were categorized as E-Statin: statin use pre-PVI through discharge (D/C) and FU or N-Statin: No statins pre-PVI, at D/C or any time during FU. The propensity score matched model (PSM) was constructed. Groups were compared using chi-square, Kaplan-Meier survival and Cox regression analysis. RESULTS: There were 9,089 index PVI in 8,402 patients; E-Statin: 7149 index PVI in 6,591 patients; and N-Statin: 1940 index PVI in 1811 patients. The mean age was 69 ± 12 years and 58% were male. Statin use was associated with improved 3-year OS-E Statin: 92.9% ± 0.9 versus N Statin: 91.1% ± 2.2%; P = 0.003; hazard ratio (HR): Exp (B) (95% confidence interval): 0.66 (0.44-0.99); P = 0.047 and remained significant following PSM: E Statin: 95.1% ± 0.2% versus 90.8% ± 0.3%; P = 0.02; HR: 0.50 (0.27-0.92); P = 0.025. No significant differences in 3-year LS or AFS were noted between the prematched groups; LS: E Statin: 83.7% ± 0.8 versus N Statin: 84.0% ± 1.7%; P = 0.89; HR: 1.09 (0.88-1.35); P = 0.44; AFS-E Statin: 77.2% ± 1.1% versus 76.1% ± 2.5%; P = 0.17; HR: 0.97 (0.79-1.18); P = 0.74. or following PSM: AFS: 80.2% ± 2.8% vs. 74.7% ± 3.9%; P = 0.53, HR: 0.92 (0.72-1.19); P = 0.54; LS 85.3% ± 1.9% vs. 83.5% ± 2.6%; P = 0.51, HR: 1.08 (0.83-1.4); P = 0.57. Statins significantly improved LS among those with renal failure: 67.8% ± 2.6% vs. 59.7% ± 4.4%; P = 0.003; HR: 56 (0.40-0.79); P = 0.001. CONCLUSIONS: Statins are independently associated with improved OS in patients who undergo PVI for CLTI and should be considered for all barring intolerance. Statin use was associated with improved LS in patients with end-stage renal disease. Additional research is needed in this area, particularly, the impact of statin therapy in high-risk CLTI subgroups.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Chang M, O'Brien-Irr M, Montross B, et al. Impact of Statins on Survival and Limb Salvage in Patients Undergoing Peripheral Endovascular Intervention for Chronic Limb-Threatening Ischemia. Ann Vasc Surg. 2022. PMID: 36503021. doi:10.1016/j.avsg.2022.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。